- Research article
- Open Access
Provider perspectives on emergency department initiation of medication assisted treatment for alcohol use disorder
BMC Health Services Research volume 22, Article number: 456 (2022)
Alcohol use disorder (AUD) is ubiquitous and its sequelae contribute to high levels of healthcare utilization, yet AUD remains undertreated. The ED encounter represents a missed opportunity to initiate medication assisted treatment (MAT) for patients with AUD. The aims of this study are to identify barriers and facilitators to the treatment of AUD in the ED, and to design interventions to address identified barriers.
Using an implementation science approach based on the Behavior Change Wheel framework, we conducted qualitative interviews with staff to interrogate their perspectives on ED initiation of AUD treatment. Subjects included physicians, nurses, nurse practitioners, clinical social workers, and pharmacists. Interviews were thematically coded using both inductive and deductive approaches and constant comparative analysis. Themes were further categorized as relating to providers’ capabilities, opportunities, or motivations. Barriers were then mapped to corresponding intervention functions.
Facilitators at our institution included time allotted for continuing education, the availability of clinical social workers, and favorable opinions of MAT based on previous experiences implementing buprenorphine for opioid use disorder. Capability barriers included limited familiarity with naltrexone and difficulty determining which patients are candidates for therapy. Opportunity barriers included the limited supply of naltrexone and a lack of clarity as to who should introduce naltrexone and assess readiness for change. Motivation barriers included a sense of futility in treating patients with AUD and stigmas associated with alcohol use. Evidence-based interventions included multi-modal provider education, a standardized treatment algorithm and order set, selection of clinical champions, and clarification of roles among providers on the team.
A large evidence-practice gap exists for the treatment of AUD with Naltrexone, and the ED visit is a missed opportunity for intervention. ED providers are optimistic about implementing AUD treatment in the ED but described many barriers, especially related to knowledge, clarification of roles, and stigma associated with AUD. Applying a formal implementation science approach guided by the Behavior Change Wheel allowed us to transform qualitative interview data into evidence-based interventions for the implementation of an ED-based program for the treatment of AUD.
Alcohol Use Disorder (AUD) is a frequent diagnosis in the Emergency Department (ED)  and the third leading cause of preventable death in the United States . An estimated 17.8% of adults experience AUD at some point during their lifetimes , leading to more than 95,000 annual deaths and an untold physical, financial, and emotional burden of disease . Of those affected, it is estimated that less than 10% are treated with appropriate medication .
Despite more than 2.2 million annual ED encounters for chronic alcohol use , a national survey of emergency department directors reported that only 15% of departments had any policy in place to screen for AUD and only 9% had a policy to perform a brief intervention ; far fewer initiate pharmacotherapy for AUD. Instead, most patients who present to the ED with AUD are managed for acute complications and discharged to follow up with primary care .
The ED encounter represents a missed opportunity. Studies show that initiating medication-assisted treatment (MAT) for substance use disorders in the ED can significantly increase engagement in addiction treatment as well as decrease use of opioids and nicotine. Similar positive results are suggested for alcohol [8, 9]. Medications for treating AUD have historically included acamprosate, disulfiram, topiramate, gabapentin, and more recently naltrexone (NTX), though none are widely used in the ED.  We have chosen to focus on the initiation of NTX because it is a first line treatment for AUD, and is the expected practice for primary care in our health system . Several trials and meta-analyses have demonstrated that NTX can help AUD patients in the outpatient setting be more accepting of treatment, maintain abstinence, and reduce heavy drinking days [11,12,13,14,15,16,17,18,19,20]. Efforts have been made to characterize and address barriers to prescribing NTX in the primary care setting, though no similar studies exist in the ED [21, 22]. Recent studies suggest that treatment with NTX can also reduce the rate of ED revisits and readmissions [23, 24]. Despite the evidence, NTX is infrequently prescribed from the ED, delineating a persistent evidence-practice gap.
One recent study demonstrated the feasibility of prescribing NTX from the ED, however reported limited follow-up and poor patient-centered efficacy for naltrexone among recipients . This study demonstrates both the difficulty of introducing an intervention into a new clinical setting and raises questions as to why outcomes differed from the primary care literature.
Implementation science is defined as “the scientific study of methods to promote the systematic uptake of research findings and other evidence-based practices into routine practice, and, hence, to improve the quality and effectiveness of health services.”  Thus, our study adopts a formal implementation science approach in order to understand the potential of ED-based AUD treatment programs and to maximize the efficacy of the proposed intervention.
The aim of this study is to identify and describe perceived barriers and facilitators to the initiation of ED-based treatment of AUD with NTX. We then apply the Behavior Change Wheel framework to map identified barriers to their appropriate intervention functions in order to design a theoretically-grounded, evidence-based program for the initiation of treatment of AUD in the ED.
The Behavior Change Wheel (BCW) is a framework used in Implementation Science to guide complex implementation design and has been used successfully in the healthcare setting [27, 28]. The framework acknowledges that at the core of any successful intervention is behavior change on the part of the stakeholders. In order to accomplish the tasks of understanding behavior and identifying appropriate intervention options, the BCW uses the COM-B model of behavior. The COM-B model assumes that a specified target behavior (B) is the result of the interaction between one’s physical and psychological capability (C), physical and social opportunity (O), and automatic and reflective motivation (M). Once identified, each of these behavioral elements can be mapped to relevant intervention functions on the BCW in order to design successful interventions. For a visual of the BCW and its COM-B components, we encourage the reader to visit the authors’ website .
Our target behavior was defined as the initiation of treatment of AUD from the ED, including prescribing and administering Naltrexone, counseling, and referring patients to further resources. The BCW framework proposes three stages of development for a behavior change intervention: Stage 1 focuses on understanding behavior; Stage 2 identifies intervention options; and Stage 3 identifies behavior change techniques and modes of delivery . The BCW framework was chosen a priori to assist in mapping qualitative findings to candidate interventions and thus optimize the chances of successful implementation of AUD treatment in the ED.
This is a qualitative study using an implementation science approach consisting of semi-structured interviews of Emergency Department staff to solicit their knowledge and perceptions of AUD treatment in the Emergency Department, and to inform the design of an ED-based AUD treatment program. Our team of clinicians and researchers met regularly throughout the process in order to review collected data, revise our interview guide, and integrate that evidence to shape the implementation plan. IRB approval was obtained from the Olive View-UCLA Medical Center IRB prior to commencement of any research.
The purpose of the provider interviews was to understand the barriers and facilitators present prior to the implementation in order to address each with targeted interventions. We developed an interview guide to explore staff perspectives on AUD, Naltrexone, and our proposed implementation. Questions focused on the challenges in caring for AUD patients, prior knowledge of NTX for AUD, concerns about the initiation of Naltrexone in the ED, and their preferences on the format for NTX-related training and education. Demographic information was collected including staff role, years of experience, and number of years at the institution. The interview guide developed for this study is provided as Additional File 1.
Olive View-UCLA Medical Center is a public, safety-net Emergency Department with an academic affiliation, emergency medicine residency, and an annual census of approximately 60,000 patients. The ED has dedicated pharmacists and social workers available 24 h a day, 7 days a week, and a substance use navigator during business hours. A substance use navigator (SUN), under the California Bridge model of care, performs the role of a care coordinator for patients experiencing SUD . As part of this model, a Bridge Clinic exists within our institution that allows patients with SUD to receive care until a primary care clinic with experience in treating SUD can be assigned.
Participants and sampling
Purposive sampling was used to identify participants from each of the following categories: attending physicians, resident physicians, nurse practitioners (NPs), nurses (RNs), nursing supervisors, clinical social workers (CSWs), and pharmacists. Participants were approached face-to-face in the Emergency Department for in-person interviews, or via email for telephone interviews. Interviews continued in each of the categories until thematic saturation was reached.
In-person interviews were held in a private office or sub-waiting room. Telephone interviews were held at the subject’s convenience. All interviews were audio-recorded after the interviewer introduced themselves, made an attempt to establish rapport with the subject, explained the study and its goals, and obtained verbal consent. No field notes were made during interviews. Interviews were intended to range from 15 to 30 min.
Researcher characteristics and reflexivity
The research team was comprised of emergency physicians and medical students. One emergency physician is an expert in SUD and is the co-director of the Bridge Clinic for opiate use disorder (MM), another is trained in research and implementation science (BRT), and a third has a prior background in harm reduction strategies (EF). During analysis, we reflected as a team on our positions and background and how they might impact the coding and interpretation of the data.
Qualitative data were anonymized and transcribed verbatim using a professional online transcription service. Transcripts were edited within a week of interview to ensure accuracy, then analyzed in Dedoose, a collaborative, cloud-based qualitative data analysis platform [31, 32]. We used both inductive and deductive approaches to analysis. We used open coding and constant comparative analysis to identify emergent patterns in the data and also applied the BCW COM-B model of behavior to identify barriers and facilitators to the target behavior. Combining these approaches to coding and analysis allowed us to link themes to the BCW and identify the corresponding intervention functions. The qualitative researchers (TP, EF, CD, BRT) met regularly during the coding process to discuss the coding, refine and consolidate identified themes, and resolve coding discrepancies. Member checking and deviant case analysis were used to enhance trustworthiness. All results are reported according to the COREQ standards for reporting of qualitative research and is included as additional file 2 .
A total of 25 interviews were conducted with various members of the emergency department, including attending physicians (n = 8), registered nurses (n = 5), resident physicians (n = 3), pharmacists (n = 3), social and clinical social workers (n = 3), nurse practitioners (n = 2), and a nurse supervisor (n = 1). Years of experience ranged from new RN graduates that had worked less than a year in the medical field, to attending physicians with up to 33 years of clinical practice. Due to COVID-19 distancing measures, on-site interviews were halted after the initial 9 interviews, and the remainder were completed virtually. No repeat interviews were conducted.
Identifying barriers, facilitators, and intervention functions
Forty-two emergent themes were identified. Themes were consolidated as specific barriers or facilitators to implementation, and further categorized as relating to capability, opportunity, or motivation under the BCW COM-B model. The complete findings, relating the facilitators and barriers, their COM-B behavioral source, and their corresponding intervention function(s) can be found in Table 1 (Capability barriers), Table 2 (Opportunity barriers and facilitators), and Table 3 (Motivation barriers and facilitators).
Capability (physical and psychological)
Capability barriers describe the physical and psychological capacity of staff to engage in the treatment of AUD. The most frequent barrier identified was a lack of familiarity with treatment options for AUD:
“I just don't think that a lot of us feel very comfortable with it [Naltrexone] because we don't really have a lot of training in it. It’s not something covered in medical school and it's not something that we currently do in the emergency department.”
ED staff also felt they lacked capacity to identify patients with AUD and to discern the patient’s interest in AUD treatment or stage of change. In order to address these gaps in knowledge, these barriers were mapped to educational, training, and enabling interventions to build providers’ capacity. Details of the educational, training, and enabling interventions can be found in Table 1.
Opportunity (physical and social)
Opportunity barriers and facilitators describe factors external to providers that impede, prompt, or modify their treatment of AUD. Ambiguity in responsibilities between medical providers and clinical social workers created confusion about who was screening for AUD and assessing patients’ readiness to change:
“It’s mostly by consult. Essentially, the doctor or the nurse contacts the social worker if the patient is interested in resources. [...] So they know we're stopping by. Because a lot of times they [the providers] consult us without asking the patient and we [clinical social workers] show up and they're like, ‘Why are you here?’”
Many physicians and clinical social workers assumed the other was responsible for initiating a discussion on AUD with patients. The BCW suggests an environmental restructure to address this barrier, which can be fulfilled by clearly defining the roles of all staff with regards to AUD treatment, and increasing dialogue between providers and clinical social workers. Some raised concern about the role of EDs in providing care that would require long-term management:
“It’s easy to start things but if we prescribe naltrexone, you say, ‘Here's your prescription,’ and they're coming back in a week for refills or two weeks because there is poor substance use disorder assistance in the community, then we're becoming a continuity clinic, which– no. It's not how the ED is supposed to be.”
Although many expressed support for MAT and were enthusiastic about the possibility of offering more for AUD patients from the ED, others were hesitant about the ED becoming a source of long-term management for SUD. To address this barrier, the BCW suggests modeling and enablement interventions. Selecting champions to model the behavior of NTX prescription to demonstrate the potential of NTX is one potential remedy. Better processes that enable transition to the primary care setting by coordinating AUD treatment and sharing educational materials with primary care colleagues are additional options.
Lack of resources and options for follow-up was an additional concern. The specific lack of capacity at SUD treatment centers, as well as insufficient social support for patients such as reliable housing, food were mentioned. Access to a phone was considered crucial:
"I'm wasting my time on doing something, if no one else help me to do something, because I can't get a hold of the patient. Giving resources, it works probably 10% of the time, if that, because maybe 10% of patients have a phone"
Enablement in this case might entail bringing phone access programs into medical centers.
Interviews with pharmacists revealed multiple logistical barriers. The hospital’s mandatory pre-approval form (referred to as prior authorization in interviews) for ordering IM NTX was problematic. Providers agreed that having to complete a pre-approval form would be a major disincentive to ordering IM NTX. Additionally, pharmacy staff considered the cost of the intramuscular form of Naltrexone prohibitive.
“With the intramuscular injection, it’s ten times more expensive per month, so that’s one issue right there. And I’m not sure in terms of insurance how well that would work for some patients.”
Modifying costs and streamlining processes are potential solutions. We sought out pharmaceutical company cost reduction programs and recommended removing the pre-approval form in addition to focusing the intervention design on the oral version of naltrexone, which was significantly more affordable and did not require authorization.
Facilitators are themes or elements that are already in place at our ED that may contribute to care for AUD patients. Identified facilitators were mostly components of opportunity and were factors external to the individual provider. They include access to regularly scheduled continuing education for physicians and nurses, the availability of ED clinical social workers, pharmacists, and substance use navigators, and the proximity of the hospital to SUD treatment centers.
Motivation (automatic and reflective)
Motivational barriers and facilitators describe the thought processes and emotional responses that providers associate with the treatment of AUD. We found that providers’ limitations in their perceived or real capabilities and opportunities (such as those described above) triggered emotional reactions of powerlessness when treating patients with chronic AUD:
“I have my streamlined protocol but I guess I'm aware that my streamlined protocol works for me for short-term management of severe withdrawal symptoms, but doesn't address the underlying problem. I guess I find it a challenge that I'm good at managing short-term, but I feel basically helpless in helping them get more definitive management of their problem.”
This emotion was reinforced by an experience of futility and a stigma against patients with AUD, assuming that such patients either did not want to quit or were unable:
“You know, it’s a loop. We see it all the time. They get out of the ER, they go to 7-Eleven, they buy the alcohol at 7-Eleven, they go outside, they drink it, they get drunk, 7-Eleven calls 911, they come back to the ER, and then from the ER, they go back to 7-Eleven.”
Furthermore, providers expressed fear that if the ED started offering more AUD services, that primary care clinics would start referring more patients with AUD to the ED, creating an influx of “difficult patients”:
“Anytime you have a service like this, the clinics [...] outside the hospital in different cities, basically, just refuse to deal with it and send everybody to the hospital.”
The BCW mapped these barriers to intervention functions of modeling, enablement, and persuasion. We will augment trainings to educate ED providers about the capability of our primary care providers to treat AUD in the clinics, draw analogies to how AUD treatment is similar to other chronic diseases, like diabetes, and celebrate examples of providers and patients who made progress through using the new treatment and referral pathways.
We found that providers had developed mental heuristics to summarize many of these emotions, communicate them to each other, and avoid frustration/complexity.
“There’s that coarse and vulgar term used that goes ‘metabolize to freedom,’ where you try to get them to the point where, clinically, they're relatively sober in their clinical state and they’re safely able to discharge. Oftentimes I feel like the piece that's missing is, once you reassess them, they can eat, they could walk, they’re safe to be discharged, I feel like oftentimes we miss that opportunity to ask them, "Hey, now that I’m finally cognitively meeting you for the first time, are you interested in quitting?"
We propose modeling using alternative catch-phrases such as “metabolize to screening” to emphasize the need to reevaluate intoxicated patients once they have sobered, including screening for AUD and assessing patient interest in treatment. A significant facilitator related to motivation is the pre-existing culture that views MAT positively, likely due to an existing successful program for opiate use disorder.
Several limitations are to be considered for this study. This is a single center study in a public emergency department. The demographics of the population served may limit generalizability of the findings. One key stakeholder group that is missing from the current study is the patients. Because of COVID restrictions, we have not yet been able to incorporate the patient perspective, however, this is an immediate next step. We also have a well-established, ED-based OUD treatment program. Its presence and success may lead providers to be more open-minded about the implementation of a similar program for AUD. This data and the use of the BCW suggests the intervention functions identified and the interventions developed will facilitate a successful implementation, however, the true success of the implementation will be seen in the next stage of this research when we measure process and patient-centered outcomes.
Although medication assisted therapy for AUD is effective , a large evidence-practice gap exists. Even in a group of medically insured patients with access to care, rates of use of pharmacotherapy for AUD are reported to be less than 10% . Efforts have been made to increase AUD treatment in the primary care setting, including increasing the uptake of AUD treatment with naltrexone, through a hub and provider model . However, a number of barriers have been described in the primary care setting, including a lack of knowledge and experience, cost, beliefs that medications cannot replace specialty addiction treatment, and alcohol-related stigma [21, 22].
As the evidence-practice gap persists, health systems have looked for other settings in which to target patients with AUD for the initiation of MAT. Recent evidence suggests that the initiation of MAT for AUD at the point of inpatient discharge not only increased the rate of MAT prescription but also lead to a decrease in unexpected 30 days ED revisits for patients with AUD [23, 24]. Alcohol related visits to the ED are common, increasing, and cost the U.S. health system billions of dollars per year [1, 36].
Past ED-based initiatives assessed the paradigm of SBIRT (Screening, Brief Intervention and Referral to Treatment) . SBIRT is widely used as the American College of Surgeons required it for hospitals to maintain their trauma center designation . Recent evidence suggests, however, that SBIRT is insufficient to improve outcomes in those with AUD . SBI alone has not been shown to be effective for severe unhealthy alcohol use and the evidence for those with some unhealthy alcohol use has been inconsistent . Screening and referral from the ED does not appear to be enough. With SBIRT (adding the Referral to Treatment), a major barrier is the failure to connect with the specialty clinic for treatment, and thus failure to initiate meaningful treatment .
The emergency department visit represents an opportune window to initiate AUD treatment because the ED visit is frequently the only point of contact with the health system for patients with SUD . The ED visit is increasingly recognized as an important point for intervention for patients with SUD , and the ED has been shown as an effective venue for MAT programs focused on the treatment of opiate use disorder . Given early successes of MAT for AUD treatment at hospital discharge and MAT for Opiate Use Disorder (OUD) in the ED, the logical extension will be to use the ED visit as a site for MAT initiation for AUD. A recent systematic review found, however, that ED-specific research into MAT for AUD is absent .
In initiating a new intervention in a busy and complex setting such as an Emergency Department, a formal approach to intervention design may increase the chances of successful uptake of the intervention. Interventions that are based in behavioral theory are more effective than those that lack a strong theoretical basis [42,43,44]. The BCW has been used in the past for stepwise assessment, stakeholder input, and intervention design that is rooted in behavioral theory [45, 46]. We chose the BCW because of its focus on provider behavior change. The BCW aided us in identifying specific intervention functions needed to change role specific provider behavior with regard to AUD treatment in the ED.
Much as in primary care, we found that the major barriers to the implementation of an AUD program in the Emergency Department included lack of knowledge and stigma associated with AUD both in terms of patients disclosing their use and also in terms of providers’ perceptions of alcohol use. Factual knowledge is easier to address, particularly in a department with a residency training program and a weekly academic conference. Other environments may not have such readily available mechanisms for group education. Stigma, however, presents a more difficult challenge. The stigma associated with patients with AUD and the discomfort with patient-provider communication is present in our ED despite the presence of an ongoing and successful MAT program for OUD. Although the OUD program was cited by participants as analogous to MAT for AUD and a potential facilitator for AUD program implementation, stigma associated with AUD is still prevalent. Individuals with AUD are less likely to engage with services if they perceive highly stigmatized views of alcoholism . Reducing stigma amongst staff about patients with AUD will be a critical part of implementation. Well planned educational interventions can reduce levels of stigma surrounding AUD . For those in settings where no prior OUD program exists, the stigma is likely to be even stronger.
In addition to the stigma related to AUD, we also heard generalizations about patients with limited English proficiency, who were assumed to have lesser knowledge of AUD when compared to English speakers. While health literacy levels and knowledge of substance use disorder is expected to vary between patients, the assumption that limited English proficiency patients are unaware of their alcohol use disorder signals underlying implicit bias on the part of the provider. Implicit bias is a much larger issue as the “othering” of patients has implications for all patient care. The explicit finding in this context emphasizes the need to include cultural humility as a core theme within the AUD education as well as the need for continued emphasis overall.
In summary, there is a large evidence-practice gap for the treatment of AUD with Naltrexone. The ED visit is a missed opportunity for intervention in the care of AUD patients and initiation of Naltrexone. ED providers are optimistic about implementing AUD treatment in the ED but described many barriers, especially related to knowledge, clarification of roles, and stigma associated with AUD. Applying a formal implementation science approach guided by the Behavior Change Wheel allowed us to transform qualitative interview data into evidence-based interventions for the implementation of an ED-based program for the treatment of AUD.
Availability of data and materials
Alcohol Use Disorder
Behavior Change Wheel
Clinical Social Worker
Substance Use Disorder
Opioid Use Disorder
White AM, Slater ME, Ng G, Hingson R, Breslow R. Trends in alcohol-related emergency department visits in the United States: results from the Nationwide emergency department sample, 2006 to 2014. Alcohol Clin Exp Res. 2018;42(2):352–9.
Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291(10):1238–45.
Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on alcohol and related conditions. Arch Gen Psychiatry. 2007;64(7):830–42.
Esser MB, Sherk A, Liu Y, et al. Deaths and years of potential life lost from excessive alcohol use — United States, 2011–2015. MMWR Morb Mortal Wkly Rep. 2020;69(39):1428–33.
Mark TL, Kassed CA, Vandivort-Warren R, Levit KR, Kranzler HR. Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend. 2009;99(1–3):345–9.
Cunningham RM, Harrison SR, McKay MP, Mello MJ, Sochor M, Shandro JR, et al. National survey of emergency department alcohol screening and intervention practices. Ann Emerg Med. 2010;55(6):556–62.
Wolf C, Curry A, Nacht J, Simpson SA. Management of Alcohol Withdrawal in the emergency department: current perspectives. Open Access Emerg Med. 2020;12:53–65.
D’Onofrio G, O’Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636–44.
Bernstein SL, D’Onofrio G. Screening, treatment initiation, and referral for substance use disorders. Addict Sci Clin Pract. 2017;12(1):18.
California Department of Health Care Services. LAC DHS Expected Practices: Outpatient medication management of alcohol Use disorder. 2019.
Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry. 1999;156(11):1758–64.
Anton RF, Moak DH, Latham P, Waid LR, Myrick H, Voronin K, et al. Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol. 2005;25(4):349–57.
Guardia J, Caso C, Arias F, Gual A, Sanahuja J, Ramírez M, et al. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Alcohol Clin Exp Res. 2002;26(9):1381–7.
Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2003;60(1):92–9.
Latt NC, Jurd S, Houseman J, Wutzke SE. Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med J Aust. 2002;176(11):530–4.
Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond E. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction. 2001;96(11):1565–73.
O’Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry. 1992;49(11):881–7.
O’Malley SS, Robin RW, Levenson AL, GreyWolf I, Chance LE, Hodgkinson CA, et al. Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial. Alcohol Clin Exp Res. 2008;32(7):1271–83.
Srisurapanont M, Jarusuraisin N. Opioid antagonists for alcohol dependence. Cochrane Database of Systematic Reviews [Internet]. 2005;(1). Available from: https://doi.org/10.1002/14651858.CD001867.pub2.
Murphy CE 4th, Wang RC, Montoy JC, Whittaker E, Raven M. Effect of extended-release naltrexone on alcohol consumption: a systematic review and meta-analysis. Addiction. 2022;117(2):271–81.
Williams EC, Achtmeyer CE, Young JP, Berger D, Curran G, Bradley KA, et al. Barriers to and facilitators of alcohol use disorder pharmacotherapy in primary care: a qualitative study in five VA clinics. J Gen Intern Med. 2018;33(3):258–67.
Alanis-Hirsch K, Croff R, Ford JH, Johnson K, Chalk M, Schmidt L, et al. Extended-release naltrexone: a qualitative analysis of barriers to routine use. J Subst Abus Treat. 2016;62:68–73.
Wei J, Defries T, Lozada M, Young N, Huen W, Tulsky J. An inpatient treatment and discharge planning protocol for alcohol dependence: efficacy in reducing 30-day readmissions and emergency department visits. J Gen Intern Med. 2015;30(3):365–70.
Stephens JR, Moore C, Stepanek KV, Garbutt JC, Starke B, Liles A, et al. Implementation of a process for initiating naltrexone in patients hospitalized for alcohol detoxification or withdrawal. J Hosp Med. 2018;13(4):221–8.
Anderson ES, Chamberlin M, Zuluaga M, Ullal M, Hawk K, McCormack R, et al. Implementation of Oral and Extended-Release Naltrexone for the Treatment of Emergency Department Patients With Moderate to Severe Alcohol Use Disorder: Feasibility and Initial Outcomes. Ann Emerg Med. 2021;S0196–0644(21):00398–X.
Bauer MS, Damschroder L, Hagedorn H, Smith J, Kilbourne AM. An introduction to implementation science for the non-specialist. BMC Psychol. 2015;3(1):32.
Phillips R, Copeland L, Grant A, Sanders J, Gobat N, Tedstone S, et al. Development of a novel motivational interviewing (MI) informed peer-support intervention to support mothers to breastfeed for longer. BMC Pregnancy Childbirth. 2018;18(1):90.
Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6(1):42.
Michie S, Atkins L, West R. The Behaviour Change Wheel Book - A Guide To Designing Interventions. Available from: http://www.behaviourchangewheel.com/. [cited 2021 Aug 30].
California Department of Health Care Services, Public Health Institute. FAQ- Substance Use Navigator (SUN). CA Bridge 2019. Available from: https://cabridge.org/. [cited 2021 Aug 29].
Dedoose. Los Angeles, CA: SocioCultural Research Consultants, LLC; Available from: www.dedoose.com.
Hewitt-Taylor J. Use of constant comparative analysis in qualitative research. Nurs Stand. 2001;15(42):39–42.
Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–57.
Rittenberg A, Hines AL, Alvanzo AAH, Chander G. Correlates of alcohol use disorder pharmacotherapy receipt in medically insured patients. Drug Alcohol Depend. 2020;214:108174.
Cousins SJ, Crèvecoeur-MacPhail D, Kim T, Rawson RA. The Los Angeles County hub-and-provider network for promoting the sustained use of extended-release naltrexone (XR-NTX) in Los Angeles County (2010-2015). J Subst Abus Treat. 2018;85:78–83.
Mullins PM, Mazer-Amirshahi M, Pines JM. Alcohol-related visits to US emergency departments, 2001-2011. Alcohol Alcohol. 2017;52(1):119–25.
Bernstein SL, D’Onofrio G. A promising approach for emergency departments to care for patients with substance use and behavioral disorders. Health Aff (Millwood). 2013;32(12):2122–8.
Surgeons AC of Alcohol Screening and Brief Intervention (SBI) for Trauma Patients. American Psychological Association; 2007. Available from: http://doi.apa.org/get-pe-doi.cfm?doi=10.1037/e560182009-001 . [cited 2021 May 8].
Glass JE, Andréasson S, Bradley KA, Finn SW, Williams EC, Bakshi A-S, et al. Rethinking alcohol interventions in health care: a thematic meeting of the international network on brief interventions for Alcohol & Other Drugs (INEBRIA). Addict Sci Clin Pract. 2017;12 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5425968/. [cited 2021 May 8].
Glass JE, Hamilton AM, Powell BJ, Perron BE, Brown RT, Ilgen MA. Specialty substance use disorder services following brief alcohol intervention: a meta-analysis of randomized controlled trials. Addiction. 2015;110(9):1404–15.
Hawk KF, Glick RL, Jey AR, Gaylor S, Doucet J, Wilson MP, et al. Emergency medicine research priorities for early intervention for substance use disorders. West J Emerg Med. 2019;20(2):386–92.
Glanz K, Bishop DB. The role of behavioral science theory in development and implementation of public health interventions. Annu Rev Public Health. 2010;31(1):399–418.
Webb TL, Sniehotta FF, Michie S. Using theories of behaviour change to inform interventions for addictive behaviours. Addiction. 2010;105(11):1879–92.
Michie S, Johnston M, Abraham C, Lawton R, Parker D, Walker A, et al. Making psychological theory useful for implementing evidence based practice: a consensus approach. Qual Saf Health Care. 2005;14(1):26–33.
Band R, Bradbury K, Morton K, May C, Michie S, Mair FS, et al. Intervention planning for a digital intervention for self-management of hypertension: a theory-, evidence- and person-based approach. Implement Sci. 2017;12(1):25.
Handley MA, Harleman E, Gonzalez-Mendez E, Stotland NE, Althavale P, Fisher L, et al. Applying the COM-B model to creation of an IT-enabled health coaching and resource linkage program for low-income Latina moms with recent gestational diabetes: the STAR MAMA program. Implement Sci. 2016;11. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870786/. [cited 2021 May 8].
Keyes KM, Hatzenbuehler ML, McLaughlin KA, Link B, Olfson M, Grant BF, et al. Stigma and treatment for alcohol disorders in the United States. Am J Epidemiol. 2010;172(12):1364–72.
Enzmann M, Reiter D, Grady SE, Ulrich E. Decreasing the stigma surrounding alcohol use disorder. Curr Pharm Teach Learn. 2021;13(1):36–41.
No sources of funding to report.
Ethics approval and consent to participate
IRB approval was obtained from the Olive View-UCLA Medical Center IRB prior to commencement of any research. Verbal, rather than written consent, was approved as the study obtained exemption status from the IRB due to the its minimal risk to subjects: the information contained in the interviews does not pertain to the subjects themselves and therefore was deemed minimal risk (no health information, no personal identifiers collected). Verbal consent was obtained via a standardized script approved by the IRB, and documented in a de-identified file where completed interviews were tracked. All interviews were audio-recorded after verbal consent was obtained.
Consent for publication
The authors declare that they have no competing interests. We have no financial relationships with the parties that manufacture or distribute naltrexone.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Philippine, T., Forsgren, E., DeWitt, C. et al. Provider perspectives on emergency department initiation of medication assisted treatment for alcohol use disorder. BMC Health Serv Res 22, 456 (2022). https://doi.org/10.1186/s12913-022-07862-1
- Alcohol use disorder
- Medication assisted treatment
- Implementation science
- Behavior change wheel